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Abstract
The development of mechanically interlocked molecular systems programmed to
operate autonomously in biological environments is an emerging field of research
with potential medicinal applications. Within this framework, functional rotaxane-
and pseudorotaxane-based architectures are starting to attract interest for the
delivery of anticancer drugs, with the ultimate goal to improve the efficiency
of cancer chemotherapy. Here, we report an enzyme-sensitive [2]-rotaxane
designed to release a potent anticancer drug within tumor cells. The molecular
device includes a protective ring that prevents the premature liberation of the drug
in plasma. However, once located inside cancer cells the [2]-rotaxane leads to
the release of the drug through the controlled disassembly of the mechanically
interlocked components, in response to a determined sequence of two distinct
enzymatic activations. Furthermore, in vitro biological evaluations reveal that this
biocompatible functional system exhibits a...
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The development of mechanically interlockedmolecular systems programmed to operate autonomously in
biological environments is an emerging ﬁeld of research with potential medicinal applications. Within this
framework, functional rotaxane- and pseudorotaxane-based architectures are starting to attract interest
for the delivery of anticancer drugs, with the ultimate goal to improve the eﬃciency of cancer
chemotherapy. Here, we report an enzyme-sensitive [2]-rotaxane designed to release a potent
anticancer drug within tumor cells. The molecular device includes a protective ring that prevents the
premature liberation of the drug in plasma. However, once located inside cancer cells the [2]-rotaxane
leads to the release of the drug through the controlled disassembly of the mechanically interlocked
components, in response to a determined sequence of two distinct enzymatic activations. Furthermore,
in vitro biological evaluations reveal that this biocompatible functional system exhibits a noticeable level
of selectivity for cancer cells overexpressing b-galactosidase.
Introduction
Over the past two decades, the design of functional interlocked
molecules1 programmed to perform specic tasks in response
to an external stimulus has received considerable attention.2–9
In particular, much eﬀort has been devoted to control the
dynamic behavior of mechanically interlocked architectures
with the ultimate goal to develop molecular motors and
machines for nanotechnological applications.2 More recently,
rotaxane- and pseudorotaxane-based devices designed to
interact with biological systems have started to emerge.3–9
Mechanized mesoporous silica nanoparticles coated with
“nanovalves”,5–7 biodegradable polyrotaxanes8 and enzyme-
responsive rotaxane-based propeptides9 have been proposed as
potential anticancer drug carriers. However, the development of
autonomous interlocked systems capable of transporting a
potent drug in a stable non-toxic form, launching its biological
activity once located inside cancer cells, still remains highly
challenging.
Here we report on the design, synthesis and operation of a
novel biocompatible [2]-rotaxane 1 programmed for the intra-
cellular delivery of a potent anticancer agent while preventing
its premature liberation in plasma (Fig. 1). To achieve such a
task in an autonomous manner, the molecular delivery system
has built into its structure a latent “chemical program” that
pilots the process of drug release through the disassembly of
the mechanically interlocked components, in response to a
determined sequence of enzymatic activations and chemical
self-immolations. The functionality of rotaxane 1 relies on the
association of several distinct units, including an enzymatic
trigger, a self-immolative linker, a self-opening macrocycle, a
hydrophilic stopper and an esterase-sensitive thread linked to
the C20–OH position of paclitaxel (Fig. 1). With this design, the
macrocycle plays the role of a temporary molecular shield pro-
tecting the ester bond from hydrolysis by plasmatic esterases,
thereby avoiding the release of the active drug in the blood-
stream. Once inside cancer cells, activation of the galactoside
trigger by b-galactosidase (Fig. 1A and B, step A) will initiate a
sequence of chemical reactions leading ultimately to the
decomposition of the interlocked architecture through the
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Fig. 1 (A) The principle of the intracellular drug delivery with functional interlocked system 1. When in the blood stream, rotaxane 1 does not
release the drug due to the presence of the protective ring that prevents hydrolysis of the esterase-sensitivemoiety. Once inside cancer cells, the
process of drug release is initiated by the activation of the galactoside trigger by intracellular b-galactosidase (step A). This is followed by a
spontaneous sequence of reactions that leads to opening of the protective ring and the concomitant disassembly of the interlocked architecture
(steps B and C). As a result the ester linkage of the thread becomes accessible to intracellular esterases that induce the liberation of the active
drug (step D). (B) Structure of rotaxane 1 and the paclitaxel release mechanism.
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 2608–2613 | 2609
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controlled opening of the protective ring (Fig. 1A and B, steps B
and C). Unmasked in this way, the ester bond of the free thread
then becomes accessible to intracellular esterases, allowing the
release of paclitaxel within the cells (Fig. 1A and B, step D). The
demonstration that an enzyme-sensitive [2]-rotaxane can be
programmed to accomplish a specic task in an autonomous
manner under the condition prevailing within living cells opens
the way for the development of functional interlocked systems
for triggered biological applications.
Results and discussion
Synthesis of rotaxane 1
The key step in the synthesis of 1 relies on the construction of
the interlocked architecture via the copper(I)-catalysed azide-
alkyne 1,3-cycloaddition (CuAAC) active-metal template
strategy.10–12
Coordination of Cu(I) to the endotopic pyridine-containing
macrocycle 8 allows azide 9 and alkyne 10 to bind to the metal
catalyst in such a way that formation of the triazole thread
occurs predominantly within the cavity of the macrocycle,
leading to the rotaxane architecture (Fig. 2).
Galactosylated ring 8 was prepared from biscarbonate 6 and
dianiline 7 (see ESI†). The macrocycle was treated with azide 9,
alkyne 10 and Cu(CH3CN)4PF6 for 45 hours at room tempera-
ture in CH2Cl2/CH3OH (87/13) to aﬀord [2]-rotaxane 1 as a
mixture of two diastereoisomers (the oﬀ-centre urethane group
of the macrocycle means that threading of the unsymmetrical
axle through the ring in diﬀerent directions produces
nonidentical structures) in 27% yield aer purication by
preparative HPLC. The rotaxane was perfectly stable over several
days in solution demonstrating that paclitaxel and the hydro-
philic bisphenol-based moiety are bulky enough to act as
stoppers, thereby avoiding premature disassembly of the
interlocked architecture.
Operation of functional interlocked system 1
Paclitaxel is a potent antimitotic agent employed clinically for
the treatment of several malignancies including ovarian, breast
and lung cancer.13 However, the antitumor eﬃcacy of this
molecule is limited by its systemic toxicity and poor aqueous
solubility. Thus, the derivatization of paclitaxel in the form of
water soluble non-toxic prodrugs have been suggested as a
valuable alternative to enhance the therapeutic index of this
compound.14 The vast majority of paclitaxel prodrugs have been
designed by introducing a promoiety to the C20–OH position of
the drug through an ester linkage. Since this hydroxyl group is
crucial for the bioactivity,15 such derivatives are usually less
toxic than paclitaxel. Furthermore, C20–OH esters can be readily
cleaved by various hydrolytic enzymes to restore the anticancer
activity of the free drug that is a requisite property for a prodrug.
This relatively high reactivity represents a signicant drawback
in this approach due to the rapid hydrolysis of these prodrugs
by plasmatic esterases preventing them reaching cancer cells. In
contrast, by reducing the accessibility of the C20–OH ester bond,
the macrocycle of rotaxane 1 should limit the esterase-mediated
degradation of the thread and the subsequent liberation of
paclitaxel in plasma.
The stability of rotaxane 1 was examined in rat plasma at
37 C and compared to that of the corresponding thread 4.
Under these conditions, prodrug 4 was rapidly cleaved leading
to the release of the free drug, conrming the instability of C20–
OH esters of paclitaxel in plasma (see ESI†). In contrast, the
interlocked system 1 was perfectly stable over a 48 hour period
without any detectable liberation of the drug. This demon-
strates that encapsulation of the thread 4 within a rotaxane
structure prevents its esterase-mediated hydrolysis in plasma.
Furthermore, compound 1 was readily soluble in plasma at a
concentration of 3.3  102 mol L1 whereas the aqueous
solubility of paclitaxel is 1.1  105 mol L1.16 The increased
solubility, which probably results from the presence of the
galactoside trigger and the Glc-TEG-based stopper,17 is signi-
cant since in the clinic the poor aqueous solubility of paclitaxel
means that it has to be administered in a vehicle containing
ethanol and Cremophor EL.
We next investigated the release mechanism of the thread 4
from the interlocked system 1 in the presence of b-galactosi-
dase (Fig. 1B). This enzyme is present only in vanishingly small
concentrations in serum and its activity is overwhelmingly
intracellular. As a result, activation of the enzymatic trigger of
the functional interlocked system 1 should take place exclu-
sively inside living cells. Furthermore, since the expression ofFig. 2 Synthesis of rotaxane 1.
2610 | Chem. Sci., 2015, 6, 2608–2613 This journal is © The Royal Society of Chemistry 2015
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b-galactosidase is much higher in several tumor types
compared to normal tissues,18–20 system 1 should be activated
preferentially within cancer cells exhibiting elevated levels of
this enzyme.
Rotaxane 1was incubatedwith the enzyme in phosphate buﬀer
(pH 7.2, 0.02M) at 37 C and the evolution of themixture over time
monitored by HPLC/HRMS (Fig. 3). The chromatograms showed
the rapid emergence (t ¼ 10 min) of two new peaks with m/z
1387.0735 and 1311.5593 ([M + 2H]2+), which correspond respec-
tively to the degalactosylated rotaxane 2 and the aniline 3 resulting
from the self-immolation of the nitro-benzyloxycarbonyl linker.21,22
Rotaxane 3 then spontaneously decomposed, enabling the
opening of the macrocycle and the subsequent release of the free
thread 4 (m/z 1034.4501, [M + 2H]2+, t ¼ 4 h). The opening
mechanism of the macrocycle was conrmed by HRMS detection
of the unstable azaquinonemethide 5 (m/z 511.2340, [M +H]+) that
degraded rapidly in the medium.23 Aer 28 hours under these
conditions, the interlocked system 1 as well as the intermediates 2
and 3 completely disappeared from themixture, whilst the amount
of thread 4 increased and then remained stable once all of 1–3 had
been consumed.
Biological evaluation
To obtain evidence for the release of paclitaxel inside cancer
cells, we rst examined the inhibition of tubulin polymeriza-
tion, the mechanism by which paclitaxel exerts its anticancer
activity. As shown by confocal microscopy imaging, incubation
of rotaxane 1 with KB tumor cells disturbed the microtubule
network like paclitaxel, while this was not observed when cells
were not treated with 1 (Fig. 4). Since the free C20–OH of
paclitaxel is essential for its bioactivity,15 this eﬀect can be
attributed to the liberation of the active drug within the
tumor cells.
This result also correlates with the high cytotoxicity observed
for compound 1 when incubated for 48 hours with KB, H661
and MDA-MB-231 cells, exhibiting IC50 values of 88.7, 144.0 and
192.3 nM respectively (Table 1). However, paclitaxel was from
3.9 to 4.7-fold more toxic on the same cancer cell lines with IC50
of 19.4, 37.3 and 41.2 nM. This diﬀerence of cytotoxicity may be
a result of the higher hydrophilicity of 1 reducing its passive
penetration through the cell membrane. Nevertheless, the lower
antiproliferative activity of rotaxane 1 is outweighed by the gain
in selectivity for cancer cells overexpressing b-galactosidase. We
measured the activity of 1 on siRNA-transfected KB cell line with
a 60% reduced expression of b-galactosidase (see ESI†).
As shown in Fig. 5, when incubated at 100 nM the enzyme-
responsive rotaxane 1 was approximately 2-fold more toxic for
non-transfected compared to transfected KB cells (with 65%
and 35% reduction of cell viability respectively). In contrast, no
signicant diﬀerence of cytotoxicity was observed with either
paclitaxel or thread 4 on both types of cells. Furthermore, when
placed in the presence of E. coli b-galactosidase, rotaxane 1
exhibited the same level of toxicity for non-transfected and
transfected KB cells. Overall, these results conrmed that the
cytotoxicity of 1 is dependent of the intracellular activity of b-
galactosidase.
Fig. 3 Enzymatic hydrolysis of rotaxane 1 with E. coli b-galactosidase
in phosphate buﬀer (0.02M, pH 7.2, 37 C)monitored by HPLC at t¼ 0,
t ¼ 10 min, t ¼ 4 h and t ¼ 28 h. Retention times: 1 (15.87 min),
2 (18.22 min), 3 (16.59 min), 4 (14.98 min).
Fig. 4 a-Tubulin immunodetection by confocal microscopy in KB
cells (human mouth epidermal carcinoma) when non-treated, treated
for 48 hours with either 100 nM of rotaxane 1 or 25 nM of paclitaxel.
Scale bar: 25 mm.
Table 1 IC50 values (nM) of paclitaxel and rotaxane 1 on KB, H661 and
MDA-MB-231 cell lines after two days treatment
KB H661 MDA-MB-231
Paclitaxel 19.4  3.1 37.3  8.0 41.2  5.0
1 88.7  10.3 144.0  3.0 192.3  19.1
This journal is © The Royal Society of Chemistry 2015 Chem. Sci., 2015, 6, 2608–2613 | 2611
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Finally, we evaluated the antiproliferative activity of the
interlocked system 1 on HUVEC normal cells. Compared to
cancer cells tested in this study, rotaxane 1 was less toxic for
HUVEC cells with only a 20% reduction of cell viability at the
highest tested dose of 500 nM (see ESI†).
The selective killing of tumor cells represents one of the
main challenges of cancer chemotherapy. As a drug delivery
system based on 1 should exhibit higher toxicity for cancer cells
expressing a high concentration of the enzyme compared to
healthy cells.
Conclusion
In summary, we developed a functional interlocked molecular
system programmed to release a potent anticancer drug within
cancer cells in response to a determined sequence of two
distinct enzymatic activations. The [2]-rotaxane includes a novel
b-galactosidase-responsive self-opening macrocycle that
enables both the eﬃcient protection and release of an anti-
cancer prodrug that is, in turn, activated by intracellular ester-
ases. Biological evaluations demonstrated that the molecular
system exhibits an appreciable level of discrimination for
cancer cells overexpressing b-galactosidase, whereas the
majority of current anticancer drugs lack intrinsic selectivity.
The sequence of events leading to the release of the active form
of the drug occurs under conditions as complex as those pre-
vailing within living cells, suggesting that this process could
operate in biochemical environments. Further studies are
underway to evaluate the potential of rotaxane-based architec-
tures as potential anticancer prodrugs.
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